{"id":"nasal-naloxone","safety":{"commonSideEffects":[{"rate":null,"effect":"Acute withdrawal syndrome (in opioid-dependent patients)"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":{"setId":"3d43b2a2-9cc3-4c14-8ae7-fea4c83a7f92","title":"NARCAN (NALOXONE HYDROCHLORIDE NASAL) SPRAY [SPORTPHARM, INC. DBA SPORTPHARM]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone competitively binds to opioid receptors (mu, delta, and kappa) with higher affinity than opioids, displacing opioids from these receptors and reversing respiratory depression, sedation, and other opioid effects. The nasal formulation allows rapid intranasal absorption for quick onset of action in emergency overdose situations. This is particularly valuable for opioid overdose reversal in community and out-of-hospital settings.","oneSentence":"Naloxone is an opioid antagonist that blocks opioid receptors to rapidly reverse opioid overdose effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:17:16.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal"},{"name":"Emergency treatment of known or suspected opioid overdose"}]},"trialDetails":[{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":"Healthspan Improvement, Aging, Longevity","enrollment":30},{"nctId":"NCT04851301","phase":"PHASE1, PHASE2","title":"Neural Mechanisms of Immersive Virtual Reality in Chronic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":259},{"nctId":"NCT07079241","phase":"NA","title":"A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-09-01","conditions":"Opioid Overdose","enrollment":1000},{"nctId":"NCT04650841","phase":"EARLY_PHASE1","title":"The Role of the Opioid System in Placebo Effects on Pain and Social Rejection","status":"NOT_YET_RECRUITING","sponsor":"Trustees of Dartmouth College","startDate":"2026-09-01","conditions":"Pain, Rejection, Placebo Effect","enrollment":60},{"nctId":"NCT03608163","phase":"PHASE4","title":"Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2019-01-08","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":4},{"nctId":"NCT05776823","phase":"NA","title":"Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2023-05-05","conditions":"Opioid Use Disorder, Overdose","enrollment":267},{"nctId":"NCT06306391","phase":"PHASE1","title":"Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2024-03-05","conditions":"Healthy","enrollment":8},{"nctId":"NCT04828005","phase":"PHASE1","title":"Pharmacodynamic Evaluation of Intranasal Nalmefene","status":"COMPLETED","sponsor":"Opiant Pharmaceuticals Inc","startDate":"2021-03-30","conditions":"Pharmacodynamic","enrollment":84},{"nctId":"NCT03897998","phase":"PHASE2","title":"Neural Correlates of Hypoalgesia Driven by Observation","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2021-11-01","conditions":"Pain, Virtual Reality, Placebo","enrollment":182},{"nctId":"NCT06262347","phase":"NA","title":"Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2024-06-13","conditions":"Opioid Use Disorder, Pregnancy Related, Substance Use","enrollment":131},{"nctId":"NCT05338632","phase":"PHASE1","title":"Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2022-06-24","conditions":"Opioid Induced Respiratory Depression, Chronic Opioid Use","enrollment":24},{"nctId":"NCT06089707","phase":"PHASE3","title":"Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-09","conditions":"Opioid Use Disorder","enrollment":25},{"nctId":"NCT05877118","phase":"NA","title":"Improving Availability of Intranasal Naloxone","status":"RECRUITING","sponsor":"Hartford Hospital","startDate":"2024-03-01","conditions":"Opioid Overdose","enrollment":84},{"nctId":"NCT04764630","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-03-01","conditions":"Healthy Subjects, Opioid Antagonist, Pharmacokinetics","enrollment":21},{"nctId":"NCT05093296","phase":"PHASE2, PHASE3","title":"Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2021-12-02","conditions":"Alcohol Use Disorder, Alcoholism, Alcohol Addiction","enrollment":62},{"nctId":"NCT05377255","phase":"PHASE1","title":"Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2022-03-28","conditions":"Opioid Overdose","enrollment":24},{"nctId":"NCT04212364","phase":"NA","title":"An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-03-15","conditions":"Overdose","enrollment":614},{"nctId":"NCT06064981","phase":"NA","title":"BE Intervention for Naloxone Uptake","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-01","conditions":"Harm Reduction","enrollment":137},{"nctId":"NCT04134767","phase":"NA","title":"Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)","status":"COMPLETED","sponsor":"April M Young","startDate":"2019-11-15","conditions":"Substance Use, HIV Infections, HCV Infection","enrollment":234},{"nctId":"NCT04303000","phase":"PHASE4","title":"Increasing Naloxone Access for Persons Who Use Opioids","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-07-11","conditions":"Naloxone","enrollment":111},{"nctId":"NCT03309449","phase":"NA","title":"A Usability Assessment of Naloxone by Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2016-08","conditions":"Drug Overdose","enrollment":138},{"nctId":"NCT03570099","phase":"","title":"Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications","status":"UNKNOWN","sponsor":"Region Skane","startDate":"2018-06-11","conditions":"Opioid Abuse","enrollment":2000},{"nctId":"NCT02700048","phase":"PHASE1, PHASE2","title":"Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2016-06","conditions":"Hypoglycemia Unawareness, Type 1 Diabetes","enrollment":11},{"nctId":"NCT05218681","phase":"NA","title":"Nursing Attitudes Towards SUD","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-11-17","conditions":"Substance Use Disorders, Stigma, Social","enrollment":170},{"nctId":"NCT05363501","phase":"PHASE1","title":"Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"Pocket Naloxone Corp","startDate":"2021-01-21","conditions":"Opioid Overdose","enrollment":76},{"nctId":"NCT04713709","phase":"PHASE1","title":"A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder","status":"COMPLETED","sponsor":"Nasus Pharma","startDate":"2021-01-31","conditions":"Opioid Overdose","enrollment":46},{"nctId":"NCT01939444","phase":"PHASE2","title":"A Pilot Study of the Bioavailability of Nasal Naloxone","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2013-08","conditions":"Drug Overdose","enrollment":5},{"nctId":"NCT05093309","phase":"NA","title":"Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone","status":"COMPLETED","sponsor":"Auburn University","startDate":"2018-09-18","conditions":"Opioid Overdose","enrollment":55},{"nctId":"NCT03518021","phase":"PHASE3","title":"Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2018-05-15","conditions":"Overdose, Drug Abuse","enrollment":286},{"nctId":"NCT02922959","phase":"NA","title":"A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2017-02-07","conditions":"Drug Overdose, Opioid-Related Disorders, Drug Addiction","enrollment":80},{"nctId":"NCT03223896","phase":"PHASE2","title":"Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2017-02-14","conditions":"Gambling, Opioid, Naloxone","enrollment":20},{"nctId":"NCT04025671","phase":"NA","title":"A Usability Assessment of Naloxone Administration by Untrained Community Members","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2017-08-23","conditions":"Harm Reduction, Opioid-use Disorder, Naloxone","enrollment":208},{"nctId":"NCT03430180","phase":"PHASE2","title":"Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder","status":"UNKNOWN","sponsor":"Finnish Institute for Health and Welfare","startDate":"2018-02-22","conditions":"Pathological Gambling, Gambling Disorder, Opioid Antagonist","enrollment":126},{"nctId":"NCT03827629","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2017-08-07","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT03827642","phase":"PHASE1","title":"A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2018-04-23","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT02307721","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-12","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT03386591","phase":"PHASE1","title":"Comparison of Naloxone Pharmacokinetics","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2018-01-03","conditions":"Opioid-use Disorder","enrollment":30},{"nctId":"NCT02158117","phase":"PHASE1","title":"Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2014-03","conditions":"Drug Overdose","enrollment":12},{"nctId":"NCT02598856","phase":"PHASE1","title":"Bioavailability of Nasal Naloxone and Injected Naloxone Compared","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2016-03","conditions":"Drug Overdose","enrollment":22},{"nctId":"NCT00716807","phase":"NA","title":"Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-01","conditions":"Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome","enrollment":46},{"nctId":"NCT01912573","phase":"PHASE4","title":"Nasal Naloxone for Narcotic Overdose","status":"UNKNOWN","sponsor":"Judith Feinberg","startDate":"2013-09","conditions":"Drug Overdose","enrollment":236},{"nctId":"NCT01622504","phase":"PHASE1","title":"Naloxone Nasal Spray Pharmacokinetic Study","status":"UNKNOWN","sponsor":"Mitovie Pharma Ltd","startDate":"2012-06","conditions":"Opioid Overdose","enrollment":6},{"nctId":"NCT01567670","phase":"PHASE2, PHASE3","title":"Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray","status":"UNKNOWN","sponsor":"Lightlake Sinclair Ltd.","startDate":"2011-08","conditions":"Binge Eating Disorder","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"nasal naloxone","genericName":"nasal naloxone","companyName":"Norwegian University of Science and Technology","companyId":"norwegian-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone is an opioid antagonist that blocks opioid receptors to rapidly reverse opioid overdose effects. Used for Opioid overdose reversal, Emergency treatment of known or suspected opioid overdose.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}